Earnings ReportCollegium reported record results, outperforming expectations with strong top and bottom line figures.
Financial StrategyThe company's commitment to shareholder value is evident through its robust share repurchase program and its strategic focus on acquiring new assets to enhance the product portfolio.
Product GrowthBelbuca, now Collegium's largest and fastest growing product, has returned to growth in prescription volume, promising continued revenue expansion.